US Nasdaq stock alert

USA

Morning Alert: Alexion Pharmaceuticals down 2.2% in 2 days 18 January 2018 11:11 EST

NEWS BITES - NORTH AMERICA

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) extended its slide on Thursday, shedding an additional 39.0c (or 0.3%) to trade at $US121.73. Trading volume was 82% of average so far today. The shares have fallen $US2.75 (or 2.2%) over the past two trading days vs. the NASDAQ-100 Index which has risen 1.0% in the same period.

SECTION 1: Technical indicators

Bearish:

The price decreased 0.6% in the last week.

The present value of USD1,000 invested one year ago is $US896 [vs $US1,345 for the NASDAQ-100 Index], for a capital loss of $US104. The total return to shareholders for 1 year is -10.4%.

Fundamental measures by comparison with the sector average [in brackets] indicate:

Undervaluation:

Total Liabilities/EBITDA of 4.6 is less than the Joseph Piotroski benchmark of <5.

Overvaluation:

Price/Earnings of 69.2 [29.8]

Return on Equity 4.6% [17.6%]

Return on Assets 3% [9.1%]

Return on Capital Employed 5.4% [15.6%]

Note

The stock is at a discount of 18.5% to the 12-month high of $US149.34 on 05 Sep, 2017. It is also at a premium of 26.6% to the 12-month low of $US96.18 on 26 May, 2017.

The stock has underperformed 70% of the NASDAQ market over the past 6 months.

Bullish:

The positive 1.79 MACD (Moving Average Convergence Divergence) indicator suggests a bullish signal (12-day minus 26-day Exponential Moving Averages). Both the 12-day and the 26-day EMA are rising - another bullish signal. In the past week, the stock's MACD has been positive in four days, a reinforcing bullish signal.

SECTION 2: Ranking

DescriptionValueRank In Market
MCap $US billion27.2In Top 4%
52-week Range (in $US)96.2-149.3
1-month Range (in $US)115.2-126.3

SECTION 3: Earnings

FY2016 Annual Report: Alexion Pharmaceuticals Net Profit up 177%

Alexion Pharmaceuticals (NASDAQ:ALXN) reported net profit for the year-ended 31 December 2016 of $US399m, up 177.1% from $US144m in the previous year.

Major changes compared with previous year:

Favourable Changes:

- Total revenue up 18.3% from $US2.6b to $US3.1b

- EBIT Margin up from 21.0% to 21.8%

- EBIT to total assets up from 4.2% to 5.1%

- Sales and marketing expenses to Sales down from 33.1% to 30.9%

- Cost of Goods Sold to Sales down from 8.9% to 8.4%

- Debt to Equity down 14.6% from 0.4 to 0.3

- Total liabilities to Total assets down 8.1% from 0.4 to 0.3

- Retained earnings to total assets up from 9.0% to 13.7%

- Total current assets to Total Assets up from 18.4% to 19.5%

- Fixed Assets to Total Assets up from 5.3% to 7.8%

- Current Debtors to Total Assets up from 4.1% to 4.9%

- Total Liabilities to EBITDA of 4.6 compares favourably with the Joseph Piotroski benchmark of less than 5. This ratio has improved by 37.3% from the previous year's ratio of 7.3.

- Total Liabilities to Operating Cash Flow of 4.2 compares favourably with the Joseph Piotroski benchmark of less than 4. This ratio has improved by 41.4% from the previous year's ratio of 7.2.

Unfavourable Changes:

- Interest cover down 39% from 11.4 to 6.9

- Profit before tax to Sales down from 19.1% to 18.7%

- Current ratio down 8.2% from 3.4 to 3.1

Note:

- Total revenue to total assets steady at 0.2

- Amortisation to Sales up from 4.5% to 10.4%

- Tax expenses to Sales down from 13.6% to 5.7%

- Working capital to total assets steady at 13.2%

- Total non-current assets to Total Assets down from 81.6% to 80.5%

- Intangibles to Total Assets down from 74.5% to 70.5%

SECTION 4: Recent Reported Selling

January 04: Alexion Pharmaceuticals director sells

Alexion Pharmaceuticals (NASDAQ:ALXN) director Ludwig Hantson sold 2,553 shares worth $US310,521 on January 02. The selling price was $US121.63. The shares hit a three-month high on the day.

SECTION 5: Recent Reported Buying

December 05 2017: Alexion Pharmaceuticals director awarded shares

Alexion Pharmaceuticals (NASDAQ:ALXN) director Christopher J. Coughlin, was awarded 10,000 shares worth $US1.1 million on December 05.

SECTION 6: Recent News of Alexion Pharmaceuticals

January 09: Alexion Pharmaceuticals (ALXN) issued new U.S. patent [9,862,767]

Alexion Pharmaceuticals (ALXN) has been issued a new U.S. patent titled "Therapeutic methods using anti-CD200 antibodies" by the US Patent and Trademark Office. The patent number is 9,862,767 and was issued on January 9, 2018.

ABSTRACT

The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer.

January 02: Alexion to Present at the 36th Annual J.P. Morgan Healthcare Conference

NEW HAVEN, Conn.---- Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2018 at 9:00 a.m., PT (12:00 p.m., ET). The Q&A breakout session will immediately follow the presentation at 9:30 a.m., PT (12:30 p.m., ET).

An audio webcast of the presentation and breakout session will be available live.

January 02: Alexion and Elliott Agree to Collaborate on Identifying a New Board Member

NEW HAVEN, Conn.---- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) said today that its Board of Directors and Elliott have agreed to work collaboratively to promptly identify a new member to join the Alexion Board. Alexion announced in November that it had a search underway to fill an open Board seat and is seeking candidates who represent a range of backgrounds, perspectives, skills, and expertise, with an emphasis on maintaining a diverse Board.

David Brennan, Chairman of Alexion's Board of Directors, said, "This agreement is in line with our ongoing efforts to maintain active and constructive dialogue with all of our shareholders and to identify a new board member with a proven track record of building value.

December 26 2017: Soliris (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)

First and Only Approved Complement Inhibitor in Japan as a Treatment for Patients with gMG, a Chronic and Debilitating Neuromuscular Disorder

NEW HAVEN, Conn.---- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Soliris (eculizumab) as a treatment for patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin (IVIG) therapy or plasmapheresis (PLEX).

December 20 2017: Alexion to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

NEW HAVEN, Conn.---- Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 4, 2018 at 1:45 p.m. Eastern Time.

An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexion.com.

Alexion Pharmaceuticals, Inc. (O:ALXN)

ISIN: US0153511094

PermID: 4295905466

CIK: 899866

CUSIP: 015351109

Source: www.BuySellSignals.com